1. Home
  2. Blog
  3. Transform in vitro assays with human iPSC-derived sensory neurons, mature in 21 days

Transform in vitro assays with human iPSC-derived sensory neurons, mature in 21 days

Why are Axol’s human iPSC-derived sensory neurons transforming in vitro models of pain and itch?

Because they faithfully recapitulate human physiology in vitro.

At Axol, we believe using human cells earlier in pre-clinical drug discovery and cosmetic research can improve the physiological relevance of cellular assays. This means more compounds will be failed faster, which will accelerate the translation of safe and efficacious compounds. Axol’s hiPSC-derived sensory neurons are robust, reliable cells for both pain and itch research and cosmetic safety screening assays. They have been shown to be suitable models for recapitulating the physiology of human disease, in a dish.

Axol hiPSC-derived sensory neurons are available from healthy and diseased patients, and are assay ready in 21 days. Axol Sensory Neuron Maximizer media works by mimicking in vivo signals between sensory neurons and their supporting cells. The supplement contains signaling factors present in the peripheral nervous system and in particular the native environment of sensory neurons. Human iPSC-derived sensory neurons treated with Maximizer express key markers, such as TRPv1, TRPa1, TRPv2, TRPv3, TRPm8, Nav1.7 and Nav1.8, in early weeks of culturing with functional responses.

Axol’s hiPSC-derived neurons and medias are manufactured in a quality manufacturing environment, undergoing stringent quality control tests. Upgrade the physiological relevance of your assays and drug discovery with Axol’s robust and reproducible hiPSC-derived sensory neurons and associated medias.

Are you going to the Safety Pharmacology Meeting in Montreal in September?

Meet Axol to discuss your sensory neuron needs. We are there from Sunday 11th September until Tuesday 13th September. Please book a convenient time:

– Meet with Jan Turner

– Meet with Margret Anne Craig

Share this post:

Related Posts

On-Demand Webinar: “CiPA Validation of hiPSC-Derived Cardiomyocytes for Drug Safety Evaluation” – June 9th